THIEME INA
No ORCID on file
· 18 papers in corpus
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…